Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). It are also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. It is a research and development (R&D)-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where there is growth potential in the future. Maintaining high standards of process innovation and quality in its R&D and manufacturing operations is critical to its brand and maintenance of long-term relationships with its customers.

The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India with an aggregate annual total installed capacity of 726.6 KL as of March 31, 2021. Its R&D laboratories focus on new product development and complex molecules, cost improvement programs, process improvements and oncology product development. To assist it with its R&D initiatives, it has established dedicated teams for new product development, complex products, oncology product development, technology transfer, life cycle management and project management.’ It has a professional and experienced management team. Its management team has demonstrated the ability to successfully build and integrate its businesses with various operating activities through their cumulative years of work experience. In particular, they have led the process through which it has created value through organic growth, built brand recognition and loyalty and identified new business opportunities.

Business area of the company

The company is in the business of making high-quality drugs by unlocking the possibilities of science.

Glenmark Life Sciences Ltd.

Caplin Point Laboratories Ltd.

FDC Ltd.

Jubilant Pharmova Ltd.

Aarti Drugs Ltd.

Hikal Ltd.

Indoco Remedies Ltd.

Procter & Gamble Health Ltd.

Wockhardt Ltd.

AMI Organics Ltd.

Advanced Enzyme Technologies Ltd.

Unichem Laboratories Ltd.

Strides Pharma Science Ltd.

Medplus Health Services Ltd.

Shilpa Medicare Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	5,182 Cr		EPS	34.1		High	423.2
Stock P/E	12.4		Net Profit Margin	NA		Low	417

Market Cap	5,182 Cr	ROE	29.9%
P/E Ratio(TTM)	12.4	EPS(TTM)	NA
P/B Ratio	2.4	Dividend Yield	5.0%
Industry P/E	63.6	Book Value	174.9
		Face Value	2.0

GLS